Affinia Gene Therapy Wins FDA Orphan Drug Status for Rare Heart Disease

Affinia Therapeutics has received Orphan Drug designation from the U.S. Food and Drug Administration (FDA) for its investigational gene therapy AFTX-201, marking another regulatory milestone in the company’s efforts to develop a treatment for BAG3-associated dilated cardiomyopathy (DCM), a rare inherited heart disease with no approved disease-modifying therapies.

The designation comes shortly after the FDA granted the therapy Fast Track designation, providing additional momentum for the clinical development of the experimental treatment.

AFTX-201 is being developed as a one-time intravenous gene therapy designed to target the underlying genetic cause of BAG3-associated DCM rather than simply managing the symptoms of heart failure. The therapy delivers a functional copy of the BAG3 gene using Affinia’s proprietary engineered adeno-associated virus (AAV) capsid, which is designed to efficiently reach heart muscle cells while requiring significantly lower doses than conventional gene therapy vectors.

According to the company, the engineered capsid can achieve effective cardiac delivery at doses five to ten times lower than those typically required by widely used AAV vectors such as AAV9 or AAVrh74. Affinia believes this approach could improve both treatment efficiency and safety.

Preclinical studies have produced encouraging results. In animal models of BAG3-associated DCM, AFTX-201 increased BAG3 protein production in the heart, restored normal cardiac function, reversed structural abnormalities associated with the disease, and demonstrated a survival benefit.

The investigational therapy is currently being evaluated in the Phase 1/2 UPBEAT clinical trial, which is enrolling patients across the United States and Canada. The study is assessing the safety and preliminary effectiveness of AFTX-201 in adults aged 18 to 55 who have genetically confirmed BAG3-associated DCM and experience heart failure symptoms that interfere with everyday activities.

Hideo Makimura, M.D., Ph.D., Chief Medical Officer at Affinia Therapeutics, described the FDA’s latest decision as an important step forward for the development program.

“Receiving Orphan Drug designation, in addition to the recent Fast Track designation, from the FDA marks a significant achievement for the AFTX-201 program,” Makimura said. “AFTX-201 is designed to address the underlying root cause of BAG3 DCM. The UPBEAT clinical trial is actively recruiting at multiple institutions, and we look forward to continuing to advance the program so we can bring this potentially transformative treatment to people living with BAG3 DCM.”

Patient advocacy organizations also welcomed the announcement.

Greg Ruf, Founder and Executive Director of the DCM Foundation, said BAG3-associated DCM is a devastating inherited heart condition that often causes early-onset progressive heart failure and premature death despite currently available treatments.

“There is no approved therapy that targets the underlying disease mechanism,” Ruf said. “The FDA’s Orphan Drug designation recognizes the urgent need for innovative treatment options for patients living with this rare condition.”

BAG3-associated DCM is caused by mutations in the BAG3 gene, resulting in reduced production of the BAG3 protein in heart muscle cells. The protein plays a critical role in maintaining healthy cardiac function, and its deficiency leads to weakening of the heart muscle over time. Patients often experience declining heart function, reduced quality of life, and shortened survival.

Published studies estimate that 2.3% to 3.6% of dilated cardiomyopathy cases worldwide are linked to BAG3 gene mutations. Although rare, the disease carries a significant clinical burden, highlighting the need for therapies that address its genetic cause.

The FDA’s Orphan Drug designation is intended to encourage the development of treatments for diseases affecting fewer than 200,000 people in the United States. Companies receiving the designation may qualify for incentives including tax credits for eligible clinical trial costs, exemption from certain FDA application fees, enhanced regulatory support, and up to seven years of market exclusivity if the therapy is ultimately approved.

With both Fast Track and Orphan Drug designations now secured, Affinia aims to accelerate the clinical development of AFTX-201 as it seeks to deliver a first-in-class genetic treatment for patients living with BAG3-associated dilated cardiomyopathy.